Enterovirus A vaccine - Beijing Vigoo Biological

Drug Profile

Enterovirus A vaccine - Beijing Vigoo Biological

Alternative Names: EV71 vaccine- Beijing Vigoo Biological; HFMD vaccine - Beijing Vigoo Biological; Vero cell-based vaccine - Beijing Vigoo Biological

Latest Information Update: 17 May 2015

Price : $50

At a glance

  • Originator Beijing Vigoo Biological
  • Developer Beijing Vigoo Biological; Jiangsu Provincial Center for Disease Control and Prevention
  • Class Enterovirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Enterovirus A infections

Most Recent Events

  • 17 May 2015 No development reported - Phase-III for Enterovirus A infections (Prevention) in China (Parenteral)
  • 01 May 2013 Beijing Vigoo Biological completes a phase II trial for Enterovirus A infections (Prevention) in China (NCT01679665)
  • 14 Mar 2013 Beijing Vigoo Biological completes a phase III trial for Enterovirus A infections (Prevention) in China (NCT01508247)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top